Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

NCT06841874 is registered in ClinicalTrials.gov with Nuvation Bio Inc. as lead sponsor.

NCT NCT06841874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06841874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC
Lead sponsor
Nuvation Bio Inc.
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

bronchogenic carcinoma, carcinoma, lung diseases, lung neoplasms, neoplasms, neoplasms by site, non small cell carcinoma of the lung, respiratory tract diseases, respiratory tract neoplasms, ros1-positive non-small cell lung cancer (nsclc), thoracic neoplasms